Ling Chen1, Lauren M LaRocque2, Orhan Efe2, Juan Wang2, Jeff M Sands3, Janet D Klein4. 1. Department of Medicine, Emory University School of Medicine, Atlanta, Georgia; Department of Internal Medicine & Geriatrics, Zhongnan Hospital of Wuhan University, Wuhan, China. 2. Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. 3. Department of Medicine, Emory University School of Medicine, Atlanta, Georgia; Department of Physiology, Emory University School of Medicine, Atlanta, Georgia. Electronic address: jeff.sands@emory.edu. 4. Department of Medicine, Emory University School of Medicine, Atlanta, Georgia; Department of Physiology, Emory University School of Medicine, Atlanta, Georgia.
Abstract
AIM: This study evaluates the effect of dapagliflozin, a SGLT2 inhibitor, on fluid or electrolyte balance and its effect on urea transporter-A1 (UT-A1), aquaporin-2 (AQP2) and Na-K-2Cl cotransporter (NKCC2) protein abundance in diabetic rats. METHODS: Diabetes mellitus (DM) was induced by injection of streptozotocin into the tail vein. Serum Na+, K+, Cl- concentration, urine Na+, K+, Cl- excretion, blood glucose, urine glucose excretion, urine volume, urine osmolality and urine urea excretion were analyzed after the administration of dapagliflozin. UT-A1, AQP2 and NKCC2 proteins were detected by western blot. RESULTS: Dapagliflozin treatment decreased blood glucose concentration by 38% at day 7 and by 47% at day 14 and increased the urinary glucose excretion rate compared with the untreated diabetic animals. Increased 24-hour urine volume, decreased urine osmolality and hyponatremia, hypokalemia and hypochloremia observed in diabetic rats were attenuated by dapagliflozin treatment. Western blot analysis showed that UT-A1, AQP2 and NKCC2 proteins are upregulated in DM rats over control rats; dapagliflozin treatment results in a further increase in inner medulla tip UT-A1 protein abundance by 42% at day 7 and by 46% at day 14, but it did not affect the DM-induced upregulation of AQP2 and NKCC2 proteins. CONCLUSION: Dapagliflozin treatment augmented the compensatory changes in medullary transport proteins in DM. These changes would tend to conserve solute and water even with persistent glycosuria. Therefore, diabetic rats treated with dapagliflozin have a mild osmotic diuresis compared to nondiabetic animals, but this does not result in an electrolyte disorder or significant volume depletion.
AIM: This study evaluates the effect of dapagliflozin, a SGLT2 inhibitor, on fluid or electrolyte balance and its effect on urea transporter-A1 (UT-A1), aquaporin-2 (AQP2) and Na-K-2Cl cotransporter (NKCC2) protein abundance in diabeticrats. METHODS:Diabetes mellitus (DM) was induced by injection of streptozotocin into the tail vein. Serum Na+, K+, Cl- concentration, urine Na+, K+, Cl- excretion, blood glucose, urine glucose excretion, urine volume, urine osmolality and urine urea excretion were analyzed after the administration of dapagliflozin. UT-A1, AQP2 and NKCC2 proteins were detected by western blot. RESULTS:Dapagliflozin treatment decreased blood glucose concentration by 38% at day 7 and by 47% at day 14 and increased the urinary glucose excretion rate compared with the untreated diabetic animals. Increased 24-hour urine volume, decreased urine osmolality and hyponatremia, hypokalemia and hypochloremia observed in diabeticrats were attenuated by dapagliflozin treatment. Western blot analysis showed that UT-A1, AQP2 and NKCC2 proteins are upregulated in DMrats over control rats; dapagliflozin treatment results in a further increase in inner medulla tip UT-A1 protein abundance by 42% at day 7 and by 46% at day 14, but it did not affect the DM-induced upregulation of AQP2 and NKCC2 proteins. CONCLUSION:Dapagliflozin treatment augmented the compensatory changes in medullary transport proteins in DM. These changes would tend to conserve solute and water even with persistent glycosuria. Therefore, diabeticrats treated with dapagliflozin have a mild osmotic diuresis compared to nondiabetic animals, but this does not result in an electrolyte disorder or significant volume depletion.
Authors: Scott C Thomson; Timo Rieg; Cynthia Miracle; Hadi Mansoury; Jean Whaley; Volker Vallon; Prabhleen Singh Journal: Am J Physiol Regul Integr Comp Physiol Date: 2011-09-21 Impact factor: 3.619
Authors: Volker Vallon; Kenneth A Platt; Robyn Cunard; Jana Schroth; Jean Whaley; Scott C Thomson; Hermann Koepsell; Timo Rieg Journal: J Am Soc Nephrol Date: 2010-07-08 Impact factor: 10.121
Authors: T Forst; R Guthrie; R Goldenberg; J Yee; U Vijapurkar; G Meininger; P Stein Journal: Diabetes Obes Metab Date: 2014-03-12 Impact factor: 6.577
Authors: Chao Ma; Jeroen H F de Baaij; Paul J Millar; Victor A Gault; Bastiaan E de Galan; René J M Bindels; Joost G J Hoenderop Journal: Nephron Date: 2019-02-22 Impact factor: 2.847
Authors: Olha Kravtsova; Ruslan Bohovyk; Vladislav Levchenko; Oleg Palygin; Christine A Klemens; Timo Rieg; Alexander Staruschenko Journal: Am J Physiol Renal Physiol Date: 2022-04-25